Pfizer has announced that European, African and Middle Eastern customers will now have access to a broad range of animal health products following the acquisition of Alpharma.


“The integration broadens the range of healthcare solutions we can offer our poultry customers,” said Hervé Le Galludec, Pfizer Animal Health poultry director for Europe, Africa and the Middle East.

“Not only are we expanding our product portfolio, we are entering into new therapeutic areas, allowing our customers more options and expertise from a single source.”

The acquisition of Alpharma is a part of the $3.6bn [£2.18bn] broader acquisition of US-based King Pharmaceuticals.

Pfizer Animal Health, now the world’s largest animal health company, will add a range of water-soluble therapeutics and probiotics for poultry to its stable of treatments.

“We are committed to working with our customers and providing expertise in all fields of poultry health,” said Dr Le Galludec. “This integration brings us closer to being a total health solutions partner for the poultry industry in Europe and around the world.”

Over the last decade Pfizer has undertaken a campaign of acquisitions buying out Pharmacia Corp in 2003, Embrex in 2007, Schering-Plough’s European brands in 2008 and Wyeth/Fort Dodge in 2009.